SEC Comment Letter 0000000000-25-003518 to OptimizeRx Corp (OPRX)
OptimizeRx Corp
Date: April 2, 2025 · CIK: 0001448431 · Accession: 0000000000-25-003518
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286224
Letter
Re: OptimizeRx Corp Registration Statement on Form S-3 Filed March 28, 2025 File No. 333-286224 Dear Stephen Silvestro:
April 2, 2025
Stephen Silvestro Chief Executive Officer OptimizeRx Corp 260 Charles Street, Suite 302 Waltham, MA 02453
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Rebekah Reed at 202-551-5332 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Trade &
Services
cc: Melissa Murawsky
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 2, 2025 Stephen Silvestro Chief Executive Officer OptimizeRx Corp 260 Charles Street, Suite 302 Waltham, MA 02453 Re: OptimizeRx Corp Registration Statement on Form S-3 Filed March 28, 2025 File No. 333-286224 Dear Stephen Silvestro: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Rebekah Reed at 202-551-5332 with any questions. Sincerely, Division of Corporation Finance Office of Trade & Services cc: Melissa Murawsky </TEXT> </DOCUMENT>